Alnylam Pharmaceuticals Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Cambridge, MA, USA
Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference therapeutics to treat rare and prevalent diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@alnylam.com
Company Overview
Industry
Biotechnology Research
Founded
2002
Headquarters
Cambridge, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Yvonne Greenstreet (Chief Executive Officer), Jeff Poulton (Executive Vice President and Chief Financial Officer), Vasant Jadhav (Chief Technology Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals uses the firstinitiallast format, so Jane Smith would be jsmith@alnylam.com.
What approved RNAi medicines does Alnylam Pharmaceuticals currently market?
Alnylam Pharmaceuticals has six FDA-approved RNAi medicines, including AMVUTTRA and ONPATTRO for ATTR amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria, Leqvio for hypercholesterolemia, and Qfitlia for hemophilia A or B.
How many people work at Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals employs approximately 2,832 people. If you need to identify and reach specific contacts there, a tool like Clay can help you build and verify a targeted list quickly.
Who leads Alnylam Pharmaceuticals as CEO?
Yvonne Greenstreet serves as Chief Executive Officer of Alnylam Pharmaceuticals. Jeff Poulton is the Executive Vice President and Chief Financial Officer, and Vasant Jadhav serves as Chief Technology Officer.
What does the Alnylam Pharmaceuticals Alnylam 2030 strategy focus on?
The Alnylam 2030 strategy, announced in January 2026, focuses on three pillars: achieving global leadership in the TTR amyloidosis market, delivering two or more new transformative medicines beyond TTR, and expanding to more than 40 clinical programs across 10 tissue types by 2030.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating